tbuckley/cabot-search huggingface dataset:
150P Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Authors: R. Kanesvaran, E. Kikuchi, H. Kitamura, J.H. Ku, L.S. Lee, T-P. Lin, H. Nishiyama, A.C.F. Ng, J. Ng, D.M.C. Poon, H.K. Seo, R.R. Shamaileh, C. Spiteri, E.M. Tan, B. Tran, Y-S. Tsai
Journal: Annals of Oncology (2022)
295TiP Assessing the benefit of NEPA (fixed combination of netupitant/palonosetron) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy
Authors: A. Molasiotis, M.S. Aapro, A. Alonzi, M. Chrápavá, K. Jordan, E.J. Roeland, L.S. Schwartzberg, C. Terrasanta, S. Olivari, G. Dranitsaris
Journal: Annals of Oncology (2022)
373P Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2
Authors: W. Fang, Q. Bu, Q. Wang, W. Zhao, L. Wang, X. Dong, P. Chen, Z. Wen, J. Jia, G. Jiang, L. Zhang
Journal: Annals of Oncology (2022)
235P Evaluation of a prognostic model for head and neck cutaneous squamous cell carcinoma using a cumulative number of risk factors
Authors: R. Doi, S. Matsushita, M. Aoki, H. Kato, M. Nakamura, S. Saito, M. Yasuda, N. Fujimoto, T. Kato, N. Baba, S. Iino, J. Asai, M. Ishikawa, H. Yatsushiro, T. Matsuya, Y. Kawahara, Y. Nakamura
Journal: Annals of Oncology (2022)
206MO Treatment patterns in patients with mantle cell lymphoma: Report of the Asia-Pacific multinational retrospective registry study
Authors: H. Cho, D.H. Yoon, D.J. Kim, K-W. Kang, J-Y. Kwak, S-M. Tan, J-O. Lee, S.Y. Oh, Y.R. Do, S.H. Jeong, H.J. Kang, Y. Koh, H.J. Kim, S-H. Kim, J.H. Won, T-Y. Chen, D.H. Yang, N.S. Chin, H-S. Eom, W.S. Kim
Journal: Annals of Oncology (2022)
389P Updated efficacy and safety of pralsetinib in Chinese patients with advanced RET fusion+ non-small cell lung cancer
Authors: Q. Zhou, Y-L. Wu, J. Zhao, J. Chang, H. Wang, Y. Fan, K. Wang, G. Wu, W. Nian, Y. Gong, Y. Sun, M. Sun, X. Wang, H. Shi, X. Zheng, M. Qin, X. Duan, Z. Shen, S. Yao, J. Yang
Journal: Annals of Oncology (2022)
306P Multimodal management and outcomes of stage III non-small cell lung cancer: KINDLE-Egypt analysis
Authors: R.A.M. Aboelhassan, M. Alm El-Din, M. Mancy, H. Farag, A.M. Belal, R.R.Y.G. Youssef, I. Saad El Din, T.I. El Nahas, M. Mokhtar Ibrahim, Y.A. Kader
Journal: Annals of Oncology (2022)
326P Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)
Authors: B.C. Cho, A. Luft, J.A. Alatorre Alexander, S. Lucien Geater, K. Laktionov, K. Sang-We, G. Ursol, M. Hussein, L. Lim Farah, C.T. Yang, L.H. Araujo, H. Saito, N. Reinmuth, Z. Lai, H. Mann, X. Shi, S. Peters, E.B. Garon, T.S.K. Mok, M.L. Johnson
Journal: Annals of Oncology (2022)
207MO Efficacy and safety of IMC-001, anti-PD-L1 antibody, in patients with relapsed or refractory extranodal NK/T cell lymphoma, nasal type (R/R ENKTL)
Authors: W.S. Kim, J-C. Jo, Y. Koh, D.H. Yang, D.H. Yoon, J.H. Kwon, G-W. Lee, K.H. Yoo, J. Oh, J.H. Lee, H.T. Kim
Journal: Annals of Oncology (2022)
203TiP Autophagy as a target for therapy in ovarian cancer: A phase II randomized trial with biomarker correlation (ATOC Trial)
Authors: L. Goenka, P. Ganesan, B. Dubashi, L. Chaturvedula, M. Rajappa, P. Manivannan, D. Gochhait, S. Vellathussery Chakkalakkoombil
Journal: Annals of Oncology (2022)
68O Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)
Authors: J.W. Valle, S. Qin, L. Antonuzzo, D. Tougeron, C-K. Lee, B.J. Tan, M. Ikeda, V. Guthrie, P. McCoon, Y.S. Lee, N. Rokutanda, M. Żotkiewicz, G. Cohen, D-Y. Oh
Journal: Annals of Oncology (2022)
66O TACE combined with apatinib in patients with intermediate and advanced hepatocellular carcionma: A prospective, multi-center, randomized clinical trial
Authors: B. Liang, Y. Ma, M. Huang, X. Zhang, L. Yu, Y. Luo, R. Liu, S. Zhou, G. Xu, H-L. Li, Z. Liao, H. Xiang, W. Lu, L. Xu, C. Zheng
Journal: Annals of Oncology (2022)
142P The predictive biomarker for immune-related adverse events (irAEs) in patients with metastatic renal cell carcinoma treated with the combination therapy of nivolumab plus ipilimumab: Musashino study-irAE
Authors: R. Kizawa, M. Kuno, S. Washino, S. Shirotake, K. Izumi, M. Inoue, M. Kagawa, H. Takeshita, Y. Hyodo, S. Kawakami, K. Saito, Y. Kageyama, M. Oyama, T. Miyagawa, Y. Miura
Journal: Annals of Oncology (2022)
148P First-line (1L) treatment (tx) patterns and criteria used to determine platinum eligibility (PE) in platinum-eligible and -ineligible (PI) patients (pts) with metastatic urothelial cancer (mUC) in South Korea (KR) and Taiwan (TW)
Authors: N. Milloy, M. Berry, R. Montgomery, C. Kluth, C. Bleasdale, M. Kirker, M. Kearney, W.E.M. Mohamed, N. Costa, J. Chang
Journal: Annals of Oncology (2022)
392P A phase II study of SAF-189s in patients with advanced ROS1 fusion-positive non-small cell lung cancer
Authors: J. Yang, J. Zhou, None M. li, Z-Y. Zhang, Y. Cheng, D.H. Chu, H. Pan, B. Wang, G. Chen, K. Wang, L. Jiang, Y. Hu, J. Shi, A-M. Hui, Y. Zhou, Z. Wu, J. Sun, Y. Tan, X. Xiang, Y-L. Wu
Journal: Annals of Oncology (2022)
357P Molecular stratification of small cell lung carcinoma subtypes by immunoexpression of ASCL1, NEUROD1, POU2F3 and YAP1 with clinicopathological correlation
Authors: S. Pasricha, H. Diwan, R. Tripathi, U. Batra, G. Gupta, A. Sharma, G. Durga, M. Kamboj, S. Nathany, M. Gupta, V.P.B. Koyyala, A. Jajodia, A. Mehta
Journal: Annals of Oncology (2022)
401P A phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors
Authors: S. Kondo, T. Koyama, A. Kawazoe, S. Iwasa, K. Yonemori, K. Shitara, Y. Nakamura, M. Saori, N. Yamamoto, J. Sato, T. Sahara, N. Hayata, S. Yamamuro, T. Kimura, L. Dutta, T. Tamai, M. Ikeda
Journal: Annals of Oncology (2022)
209MO Impact of CMV reactivation on survival and relapse following allogeneic stem cell transplantation for de novo myeloid sarcoma
Authors: B.J. McCormick, J.J. Kuhlman, Z. Abdel Rahman, V. Roy, J. Foran, T. Badar, M. Iqbal, S. Ailawadhi, M.A. Kharfan-Dabaja, H.S. Murthy
Journal: Annals of Oncology (2022)
149P A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Authors: L.S. Lee, R. Kanesvaran, E. Kikuchi, H. Kitamura, J.H. Ku, T-P. Lin, H. Nishiyama, A.C.F. Ng, J. Ng, D.M.C. Poon, H.K. Seo, R.R. Shamaileh, C. Spiteri, E.M. Tan, B. Tran, Y-S. Tsai
Journal: Annals of Oncology (2022)
76MO Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
Authors: J.O. Park, D.T. Wai Meng, A. Hollebecque, M. Borad, L. Goyal, A. Schram, P. Cassier, S.D. Kamath, E. Dotan, R. Kim, V. Sahai, C-Y. Liao, M. Millward, D. Roda Perez, R. Blakesley, B. Wolf, V. Subbiah, R.K. Kelley, D-Y. Oh
Journal: Annals of Oncology (2022)
78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)
Authors: D-Y. Oh, A.R. He, S. Qin, L-T. Chen, T. Okusaka, A. Vogel, J.W. Kim, T. Lee, M.A. Lee, M. Kitano, H.A. Burris, M. Bouattour, S. Tanasanvimon, R.E. Zaucha, A. Avallone, J.E. Cundom, N. Rokutanda, M. Żotkiewicz, G. Cohen, J.W. Valle
Journal: Annals of Oncology (2022)
49P Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapy: Final results of the phase II RE-ExPEL study
Authors: T.O. Goetze, A. Stein, S. Lorenzen, T. Habibzade, E. Goekkurt, P. Herhaus, D. Sookthai, K. Ihrig, C. Pauligk, S-E. Al-Batran
Journal: Annals of Oncology (2022)
304TiP Minimal residual disease (MRD)-guided adjuvant tislelizumab after adjuvant chemotherapy in resected stage IIA-IIIB non-small cell lung cancer (NSCLC): A single-arm phase II study (Seagull)
Authors: F. Li, W. Li, Y. Yang, Z. He, D. Liu, H. Guo, T. Zheng, S. Yue, Y. Ma, W. Li, Y. Qi
Journal: Annals of Oncology (2022)
329P ORCHARD: Osimertinib + necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinib
Authors: J.W. Riess, J.A. De Langen, Z. Piotrowska, S.B. Goldberg, J.W. Goldman, I. Okamoto, S. Ponce Aix, S. Teraoka, H. Ambrose, K.H. Tang, J. Maidment, B. Merchan Ruiz, N. Hewson, J. Cosaert, H.A. Yu
Journal: Annals of Oncology (2022)
64P Clinical profile and treatment outcome of patients with non-metastatic colon cancer: A single institutional study from India
Authors: S. Ganguly, N. Mukherjee, K. Ray, S. Mandal, A. Dasgupta, M. Mallath, T. Chawla, M. Ray, A. Pipara, B. Biswas, S. Roy, J. Ghosh
Journal: Annals of Oncology (2022)
402P Phase I study of selumetinib in Chinese pediatric and adult patients (pts) with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): Interim results
Authors: X-J. Yuan, X. Zhang, Q. Li, Z. Wang, C. Li, Y. Liu, X. Ge, J. Zhao
Journal: Annals of Oncology (2022)
395P Molecular landscape of Indian NSCLC: Is NGS the answer?
Authors: U. Batra, S. Nathany, M. Sharma, A. Bansal, A.B. P, S. Pasricha, A. Mehta, S. Dhandha, D. Kumar, M.K. Panigrahi, S. Mattoo
Journal: Annals of Oncology (2022)
394P Research of the algorithm for rare driver genes in non-small cell lung cancer using pathological images and artificial intelligence
Authors: K. Yoh, S. Matsumoto, Y. Sugawara, Y. Hirano, J. Iwasawa, T. Inoue, K. Mizuno, W. Kochi, M. Amamoto, D. Maeda, K. Goto
Journal: Annals of Oncology (2022)
334P Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Geographic region subgroups in EMPOWER-Lung 1
Authors: G.F. Ho, A. Sezer, S. Kilickap, M. Gumus, I. Bondarenko, M. Ozguroglu, M. Gogishvili, X. He, G. Gullo, P. Rietschel, R.G. Quek
Journal: Annals of Oncology (2022)
42TiP A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitors
Authors: N.I. Khushalani, H. Shue, C. Gedye, A. Mazumder, S. Sharma, M. Eastgate, M. Majem Tarruella, M. Antonanzas Basa, H. Montaudie, R. Marais-Nieman, L. de la Cruz Merino, A. Clements, L. Mortier, M. Jameson, F. Shojaei, J. Ning, L. Aiyer, M. Gillings, F. Kabbinavar, P. Ascierto
Journal: Annals of Oncology (2022)
LBA3 Tumor Treating Fields (TTFields) therapy plus XELOX chemotherapy for front line treatment of advanced unresectable gastroesophageal junction adenocarcinoma (GEJC) or gastric adenocarcinoma (GC): A multicenter phase II trial
Authors: J. Li, S. Cang, Y. Ling, K.O. Lam, Y. Chen, Y. Xu, Y. Yang, G. Lavy-Shahaf, J. Zhang
Journal: Annals of Oncology (2022)
264P Updated analysis of entrectinib in a subset of Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with NTRK fusion-positive (fp) solid tumours and ROS1-fp non-small cell lung cancer (NSCLC)
Authors: S. Lu, Y. Fan, C-H. Chiu, Y. Yu, H.H.F. Loong, C-C. Lin, X. Dong, J. Li, J. Zhao, Z. Zhang, N. Zhao, T. Xu, M. Hou, D. Wang, X. Hu
Journal: Annals of Oncology (2022)
63P Tumor sidedness and clinicopathological features of colorectal cancer in Medical Oncology Department, Yangon General Hospital: A retrospective review
Authors: T. Tun, L.H. Myo, E.H. Myint Yi, M.M. Maw, T. Kyaw, S.S. Win, Z. Thynn, S.Y. Myint
Journal: Annals of Oncology (2022)
151P Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: Real-world analysis of chemotherapy use and impact on patient outcomes
Authors: A. Hiong, P. Dundee, N. Lawrentschuk, J. Lynam, P. Manohar, S. Sengupta, A.J. Weickhardt, S.S.L. Wong, A.Y. Zhang, P. Gibbs, B. Tran
Journal: Annals of Oncology (2022)
1MO The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina study
Authors: Z. Shao, T. Huang, Z. Fan, Y. Wang, X. Yan, H. Yang, S. Wang, D. Pang, H. Li, H. Wang, C. Geng, L. Huang, A. Siddiqui, B. Wang, B. Xie, G. Sun, E. Restuccia
Journal: Annals of Oncology (2022)
90P Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma
Authors: G. Azzi, M. Tavallai, V. Aushev, A.E. Koyen Malashevich, G. Botta, M. Tejani, D.L. Hanna, S. Krinshpun, M. Malhotra, P. Olshan, A. Jurdi, A. Aleshin, P.M. Kasi
Journal: Annals of Oncology (2022)
47P Safety and efficacy evaluation of long-course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer: Intermediate results of a multicenter, phase II study
Authors: Z. Yang, J. Gao, X. Zhang, G. Wu, W. Deng, Y. Liu, J. Zhang, G. Chen, R. Xu, J. Han, A. Li, G. Liu, Y. Sun, D. Kong, Z. Bai, H. Yao, Z. Zhang
Journal: Annals of Oncology (2022)
335P Real-world data of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression (HOT/NJLCG2001)
Authors: H. Yokouchi, H. Mizugaki, Y. Ikezawa, R. Morita, K. Tateishi, K. Yokoo, T. Sumi, H. Kikuchi, A. Nakamura, None M. kobayashi, M. Aso, Y. Tsukita, F. Yoshiike, M. Furuta, H. Tanaka, M. Sekikawa, T. Hachiya, K. Nakamura, Y. Kitamura
Journal: Annals of Oncology (2022)
28P Development 68Ga trastuzumab Fab and bioevaluation by PET imaging in HER2/neu-expressing breast cancer patients
Authors: Y. Rathore, J. Shukla, T. Lakhanpal, I. Laroiya, A. Deep, R. Kumar, H. Singh, A. Bal, G. Singh, K. Thakur, B.R. Mittal
Journal: Annals of Oncology (2022)
182MO Immune co-regulator (co-reg) expression in mismatch repair-deficient (MMRd) endometrial cancer (EC) patients (pts): Anti-PD-(L)1-responders (R) versus (vs) non-responders (NR)
Authors: J.F. Grau Béjar, E. Yaniz Galende, C. Genestie, J-Y. Scoazec, E. Edmond, A. Le Formal, F. Blanc-Durand, J. Michels, M. Kfoury, P. Morice, P. Pautier, E. Colomba-Blameble, A. Leary
Journal: Annals of Oncology (2022)
93P Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Authors: T. Okusaka, M. Kitano, M-H. Chen, J-S. Chen, V.S. Ostwal, M.G. McNamara, V. Breder, M. Petrova, G. Buchschacher, N. Rokutanda, J. Xiong, G. Cohen, D-Y. Oh
Journal: Annals of Oncology (2022)
48P Long-term clinical outcomes after the second metastasectomy in patients (pts) with resected metastatic colorectal cancer (mCRC)
Authors: S. Choi, M. Kang, J-W. Kim, J.W. Kim, Y. Hwang, J.H. Jeon, H-K. Oh, H.W. Lee, J.Y. Cho, D-W. Kim, S. Cho, J.H. Kim, K. Kim, S-B. Kang, S. Jheon, K-W. Lee
Journal: Annals of Oncology (2022)
86P Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Authors: A.R. He, J.W. Valle, C-K. Lee, M. Ikeda, P. Potemski, C. Morizane, J.E. Cundom, D. Tougeron, F. Dayyani, N. Rokutanda, J. Xiong, G. Cohen, D-Y. Oh
Journal: Annals of Oncology (2022)
312P ClinMatch: A clinical trial matching platform that improves trial accessibility among NSCLC patients through comprehensive genomic and clinical profiling
Authors: A.C.S. Yu, A.K-Y. Yim, S.F. Nyaw, K.K-M. Li, Y.M. Lau, S.C.M. Li, S.T.F. Mok, G. Tang, A. Chang, V. Prêtre, N. Jin, A.K.L. Kai, T.C.M. Kan, H.C. Lee, T.F. Chan, C.S-C. Wong, W.C.S. Cho, H.H.F. Loong
Journal: Annals of Oncology (2022)
275MO Phase III double blind placebo-controlled study of olanzapine for chemotherapy related anorexia in patients with advanced gastric, hepatopancreaticobiliary and lung cancer
Authors: S.L. Singuluri, N. Srinivasan, L. Goenka, B. Dubashi, S. Kayal, K.T. Harichandrakumar, R. Govindarajalou, P. Ganesan
Journal: Annals of Oncology (2022)
4MO Prognostic implication of 21-gene expression assay in luminal B type hormone receptor-positive breast cancer patients younger than 40 years
Authors: J. Hyung, S. Lee, J. Kim, H.J. Kim, B. Ko, B-H. Son, J. Lee, H.J. Lee, G. Gong, H. Lee, H. Jeong, J-H. Jeong, J.E. Kim, J-H. Ahn, K.H. Jung, S-B. Kim
Journal: Annals of Oncology (2022)
89P Radiotherapy followed by camrelizumab for unresectable biliary tract cancer: A phase II clinical trial
Authors: Z. Peng, M. Zhu, M. Jin, S. Shen, H. Xiao, G. Wei, Q. He, B. Li, Y. Bao, S. Peng, Y. Chen, M. Kuang
Journal: Annals of Oncology (2022)
259MO A predictive score of cancer immunotherapy responses based on ecological analysis of gut microbiota
Authors: L. Derosa, C. Alves Costa Silva, V. Iebba, B. Routy, A. Reni, C. Audigier-Valette, G. Zalcman, J. Mazieres, S. Friard, F. Goldwasser, D. Moro-Sibilot, A. Scherpereel, H. Pegliasco, S. Martinez, B. Escudier, D. Planchard, L. Albiges, B. Besse, F. Barlesi, L. Zitvogel
Journal: Annals of Oncology (2022)
91P Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in advanced biliary tract cancer (BTC)
Authors: L. Antonuzzo, H. Takahashi, J.O. Park, A. Sookprasert, R. Gillmore, S-S. Yang, J.E. Cundom, M. Petrova, G.M. Vaccaro, M. Holmblad, J. Xiong, K. Heider, N. Rokutanda, D-Y. Oh
Journal: Annals of Oncology (2022)
349P EXPLORE-LC: A multi-site real-world evidence research platform for non-small cell lung cancer in Asia-Pacific
Authors: K.C. Toh, X. Zhao, J.H. Kim, G. Stratton, H-W. Lin, D.H. Lee, S. Yoon, Y-F. Fang, K-C. Chang, R.G. Stirling, J.R. Zalcberg, H.A. Jung, H.Y. Yu, S.M. Lim, S. Lim, K-P. Chou, None J.A. kim, D. Patel, N. Kleinman
Journal: Annals of Oncology (2022)
315P Molecular testing in lung squamous cell carcinoma using DNA- and RNA-based next-generation sequencing: A single-center experience
Authors: L. Brcic, M. Zacharias, S. Konjic, K. Kashofer, G. Absenger, P.J. Jost, R. Wurm, J. Lindenmann, A. Terbuch
Journal: Annals of Oncology (2022)
126P Late line FOLFOX therapy after prior cisplatin-based regimen in advanced esophageal squamous cell carcinoma: A multi-institutional retrospective study
Authors: K. Shimozaki, K. Sugiyama, S. Koya, K. Shiraishi, M. Okada, Y. Matsubara, M. Furuta, S. Hirose, A. Komori, S. Mitani, S. Boku, T. Nishimura, K. Tsuchihashi, Y. Kito, A. Sugaya, T. Masuishi, T. Matsumoto, T. Tsuzuki, T. Yoshii, K. Hirata
Journal: Annals of Oncology (2022)
425P Preliminary study: Assessment of public trust in traditional medicine and medical treatment in cancer patients in Indonesia - Study validity and reliability of the Universitas Sebelas Maret Trust and readiness assessment for cancer patients (UNS – TRAfCP35) questionnaire
Authors: W. Soewoto, M.D.P.P. Putra, G.S.S. Putra, R.V.V. Septiani, M. Muamar, I.R. Saadhi, M. Ardianti, M.F. Salafudin, D.A. Setiawati, R.A. Hutabarat, D.K. Prasetyo
Journal: Annals of Oncology (2022)
81P Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)
Authors: I-H. Kim
Journal: Annals of Oncology (2022)
122P Efficacy and safety of mFOLFOX-6 in advanced gastric cancer: A prospective observational study
Authors: B.P. Amrith, V. Goel, S. Joga, V.P.B. Koyyala, S. Goyal, U. Batra, D.C. Doval, V. Talwar
Journal: Annals of Oncology (2022)
316P Phase II study of ramucirumab and docetaxel for platinum-resistance NSCLC patients with malignant pleural effusion: Analysis of pleural effusion control rate
Authors: R. Ogata, S. Takemoto, M. Fukuda, H. Senju, K. Nakatomi, N. Sugasaki, H. Tomono, T. Suyama, M. Shimada, K. Akagi, F. Hayashi, Y. Dotsu, H. Taniguchi, H. Gyotoku, H. Yamaguchi, S. Nagashima, H. Soda, A. Kinoshita, H. Mukae
Journal: Annals of Oncology (2022)
92P Safety of liver resection following atezolizumab plus bevacizumab treatment in hepatocellular carcinoma (HCC) patients with macrovascular invasion: A pre-specified analysis of the TALENTop study
Authors: H. Sun, F. Shen, X. Bai, L-X. Liu, B-D. Xiang, T. Song, M. Chen, M. Kuang, Z-Y. Huang, D. Li, T. Wen, H-T. Zhao, Y-Y. Zeng, X. Zhu, J. Zhou, J. Fan
Journal: Annals of Oncology (2022)
143P Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Authors: S. Iwasa, R. Mizuno, Y. Yasumizu, N. Tanaka, T. Takeda, K. Matsumoto, S. Morita, T. Kosaka, H. Asanuma, M. Oya
Journal: Annals of Oncology (2022)
131TiP ASCEND: Randomized, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in untreated metastatic pancreatic ductal adenocarcinoma - An Australasian Gastro-Intestinal Trials Group (AGITG) trial ACTRN12621001290886
Authors: A. Dean, T.J. Price, K. Sjoquist, N. Aryal, J. Mumford, F. Day, S. Yip, A. Walsh, D. Siu, C. Jackson, S. Padinharakam, B. Lee, M. Burge, J. Lynam, N. Tebbutt, Z.W.J. Wong, L.L. Lam, J. Lee, L. Chantrill, M. Harris
Journal: Annals of Oncology (2022)
333P Efficacy and safety of immune checkpoint inhibitors alone or combined with chemotherapy in pulmonary sarcomatoid carcinoma
Authors: H. Kaneda, D. Hazama, H. Kodama, A. Miyazaki, K. Azuma, Y. Kawashima, Y. Sato, K. Ito, Y. Shiraishi, K. Miura, T. Takahama, S. Oizumi, Y. Namba, S. Ikeda, S. Miura, M. Tachihara
Journal: Annals of Oncology (2022)
LBA11 Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study
Authors: C. Zhou, Y. Lu, S-W. Kim, T. Baisamut (Reungwetwattana), J. Zhou, Y. Zhang, J. He, J. Yang, Y. Cheng, S-H. Lee, J. Chang, J. Fang, Z. Liu, L. Bu, L. Qian, T. Xu, V. Archer, M. Hilton, M. Zhou, L. Zhang
Journal: Annals of Oncology (2022)
LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722
Authors: T.S.K. Mok, K. Nakagawa, K. Park, Y. Ohe, N. Girard, H.R. Kim, Y-L. Wu, J. Gainor, S-H. Lee, C-H. Chiu, K. Sang-We, Y. Cheng-Ta, W. Liang, L. Wu, M-C. Lin, J. Samol, X. Zhang, J. Sylvester, S. Li, J.C-H. Yang
Journal: Annals of Oncology (2022)
342P Prognostic implications of PD-L1 co-expression among Filipino EGFR MT mNSCLC
Authors: H.G. Luna, E. Prieto, B.R. Dimayacyac-Esleta, M.S. Imasa, N.S. Juat, K.V. Hernandez, T.M. Sayo, G.R. Cristal-Luna, S.M. Asur-Galang, M. Bellengan, K.J.L. Duga, B.B. Buenaobra, M. De los Santos, D. Medina, J. Samo, V.M. Literal, S. Sy-Naval
Journal: Annals of Oncology (2022)
404P Adolescent &amp; young adult cancers (AYA): Experience from a large rural teaching hospital in South India
Authors: V.M. Godkhindi, S. Mailankody, K.S. Udupa, A. Pai, R. Kudva, G. V, K. Pai, M. Mathew, S. PS, S. Sharma, B.M. Singh, D. Nayak, C. Babu K Udupa, D. HC
Journal: Annals of Oncology (2022)
336P Spatial characterisation of immune microenvironment in malignant pleural mesothelioma
Authors: D. Shek, S.A. Read, W-H. Yoon, J. Mo, L. Akhuba, J. Lai, B. Gloss, L. Ma, H.E. Zhang, M. Carlino, B. Gao, G. Ahlenstiel
Journal: Annals of Oncology (2022)
22MO Efficacy and safety of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer (mTNBC) by baseline HER2 expression level: Subgroup analysis from a phase IIb trial
Authors: B. Xu, F. Ma, S. Wang, Z. Tong, W. Li, X. Wu, X. Wang, T. Sun, Y. Pan, H. Yao, X. Wang, T. Luo, J. Yang, X. Zeng, W. Zhao, X.J. Cong, N. Wang, C. Xu, J.J. Chen
Journal: Annals of Oncology (2022)
345P First-line gemcitabine-platinum chemotherapy in relapsed or metastatic pulmonary lymphoepithelioma-like carcinoma: A tertiary centre experience
Authors: G.T.C. Cheung, K.M. Cheung, J.C-H. Chow, K.H. Au, H.H.Y. Yiu
Journal: Annals of Oncology (2022)